...
首页> 外文期刊>Cell and Tissue Research >Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis
【24h】

Mesenchymal stromal cell-derived extracellular vesicles: regenerative and immunomodulatory effects and potential applications in sepsis

机译:间充质基质细胞衍生的细胞外囊:再生和免疫调节效果和脓毒症的潜在应用

获取原文
获取原文并翻译 | 示例
           

摘要

Mesenchymal stromal (stem) cells (MSCs) have multipotent differentiation capacity and exist in nearly all forms of post-natal organs and tissues. The immunosuppressive and anti-inflammatory properties of MSCs have made them an ideal candidate in the treatment of diseases, such as sepsis, in which inflammation plays a critical role. One of the key mechanisms of MSCs appears to derive from their paracrine activity. Recent studies have demonstrated that MSC-derived extracellular vesicles (MSC-EVs) are at least partially responsible for the paracrine effect. MSC-EVs transfer molecules (such as proteins/peptides, mRNA, microRNA and lipids) with immunoregulatory properties to recipient cells. MSC-EVs have been shown to mimic MSCs in alleviating sepsis and may serve as an alternative to whole cell therapy. Compared with MSCs, MSC-EVs may offer specific advantages due to lower immunogenicity and higher safety profile. The first two sections of the review discuss the preclinical and clinical findings of MSCs in sepsis. Next, we review the characteristics of EVs and MSC-EVs. Then, we summarize the mechanisms of MSC-EVs, including tissue regeneration and immunomodulation. Finally, our review presents the evidences that MSC-EVs are effective in treating models of sepsis. In conclusion, MSC-EVs may have the potential to become a novel therapeutic strategy for sepsis.
机译:间充质基质(茎)细胞(MSCs)具有多能分化能力,并存在几乎所有形式的产后器官和组织。 MSCs的免疫抑制和抗炎特性使其成为治疗疾病的理想候选者,例如败血症,其中炎症起着关键作用。 MSCS的一个关键机制似乎从其帕拉卡碱活动中获得。最近的研究表明,MSC衍生的细胞外囊泡(MSC-EV)至少部分地对旁静脉作用负责。 MSC-EVS转移分子(例如蛋白质/肽,mRNA,microrna和脂质),具有免疫细胞的免疫调节性质。已经显示MSC-EVS以模拟MSCs缓解败血症,并且可以作为全细胞疗法的替代品。与MSCs相比,MSC-EV可以提供由于较低的免疫原性和更高的安全性,因此提供了特异性优势。审查的前两部分讨论了败血症中MSCs的临床前和临床发现。接下来,我们审查了EVS和MSC-EV的特征。然后,我们总结了MSC-EVS的机制,包括组织再生和免疫调节。最后,我们的评论提出了MSC-EVS在治疗败血症模型方面有效的证据。总之,MSC-EV可能有可能成为败血症的新治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号